Skip Navigation

Europace 2003 5(s1):S5-S19; doi:10.1016/j.eupc.2004.07.003
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Savelieva, I.
Right arrow Articles by John Camm, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Savelieva, I.
Right arrow Articles by John Camm, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Atrial fibrillation and heart failure: natural history and pharmacological treatment

Irina Savelieva and A. John Camm*

Department of Cardiac and Vascular Sciences, St George's Hospital Medical School, Cranmer Terrace London SW17 0RE, United Kingdom

Atrial fibrillation (AF) is the most common sustained arrhythmia. Congestive heart failure (CHF), an increasingly frequent cardiovascular disorder affecting millions of people world-wide, has become the most important risk factor of AF in developed countries, as a result of ageing populations. Approximately two thirds of patients with CHF are >65 years of age and likely to have AF as a coexistent complication. Epidemiological surveys and large clinical trials in CHF provide strong evidence that AF is a marker of increased mortality. AF may compromise LV systolic function and worsen CHF through poor rate control, irregularity of ventricular response, and loss of atrial systolic activity. Furthermore, enhanced adrenergic stimulation in the setting of CHF facilitates AV conduction and promotes the progression of cardiomyopathy, and AF may worsen CHF as a consequence of the negative inotropic effects of drugs used to control the heart rate of rhythm, or of the proarrhythmic effects of drugs used to maintain sinus rhythm. This article reviews the putative mechanisms behind atrial remodelling due to long-standing AF, and the role of neuro-hormonal alterations in the atrial electrophysiologic and structural changes which facilitate its perpetuation. It also reviews and discusses various controlled trials of angiotensin-converting enzyme inhibitors and AT-1 receptor blockade in the perspective of AF treatment and prevention. Finally the role of specific antiarrhythmic drugs, the respective advantages and shortcomings of rate versus rhythm control in patients with AF and CHF, and the important issue of chronic anticoagulation are presented in the light of time-tested therapies, as well as new promising therapeutic approaches.

Key Words: atrial fibrillation, heart failure, atrial remodelling, angiotensin-converting enzyme inhibition, angiotensin receptor blockade, antiarrhythmic drug, anticoagulation, epidemiology of atrial fibrillation, pharmacology of atrial fibrillation

*Corresponding author. Tel.: +44 20 8725 3554; fax: +44 20 8767 7141. E-mail address: jcamm{at}sghms.ac.uk (A. John Camm).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EuropaceHome page
F. Lu, C. Jun-xian, X. Rong-sheng, L. Jia, H. Ying, Z. Li-qun, and D. Ying-nan
The effect of streptomycin on stretch-induced electrophysiological changes of isolated acute myocardial infarcted hearts in rats
Europace, August 1, 2007; 9(8): 578 - 584.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.